VSTM 3.79 (-4.29%)
US92337C1045BiotechnologyBiotechnology

Verastem (VSTM) Stock Highlights

3.79 | -4.29%
2024-11-21 05:34:53
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The companys first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The companys product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.

Statistics

Range Today
3.75 4
Volume Today 458K
Range 1 Year
2.1 14.22
Volume 1 Year 135.09M
Range 3 Year
2.1 36.24
Volume 3 Year 214.25M
Range 10 Year
2.1 148.2
Volume 10 Year 480.66M

Highlights

Market Capitalization 158.96M (small)
Floating Shares 44.32M
Current Price 3.79
Price To Earnings -1.03
Price To Revenue 12.52
Price To Book 14.36
Earnings Per Share -3.52
Payout Ratio 0%

Performance

Latest -4.29%
1 Month +26.33%
3 Months +51.6%
6 Months -66.84%
1 Year -40.5%
3 Years -89.47%
5 Years -64.91%
10 Years -96.41%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.